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Background: Emerging evidence suggests that androgens and estrogens have a role in respiratory health, but
it is largely unknown whether levels of these hormones can affect lung function in adults from the general
population. This study investigated whether serum dehydroepiandrosterone sulfate (DHEA-S), a key precur-
sor of both androgens and estrogens in peripheral tissues, was related to lung function in adult women par-
ticipating in the European Community Respiratory Health Survey (ECRHS).
Methods: Lung function and serum DHEA-S concentrations were measured in n = 2,045 and n = 1,725 women
in 19992002 and in 20102013, respectively. Cross-sectional associations of DHEA-S levels (expressed as
age-adjusted z-score) with spirometric outcomes were investigated, adjusting for smoking habits, body mass
index, menopausal status, and use of corticosteroids. Longitudinal associations of DHEA-S levels in
19992002 with incidence of restrictive pattern and airflow limitation in 20102013 were also assessed.
Findings: Women with low DHEA-S (z-score<-1) had lower FEV1 (% of predicted, adjusted difference: -2.2;
95%CI: -3.5 to -0.9) and FVC (-1.7; 95%CI: -2.9 to -0.5) and were at a greater risk of having airflow limitation
and restrictive pattern on spirometry than women with higher DHEA-S levels. In longitudinal analyses, low
DHEA-S at baseline was associated with a greater incidence of airflow limitation after an 11-years follow-up
(incidence rate ratio, 3.43; 95%CI: 1.91 to 6.14).
Interpretation: Low DHEA-S levels in women were associated with impaired lung function and a greater risk
of developing airflow limitation later in adult life. Our findings provide new evidence supporting a role of
DHEA-S in respiratory health.
Funding: EU H2020, grant agreement no.633212
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license.
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Evidence before this study
We searched Pubmed for articles using the terms (“lung
function” OR “pulmonary function” OR “airflow obstruction”)
AND (“DHEA-S” OR “DHEA” OR “Sex steroids” OR “Sex hor-
mones”), with no date restrictions and not limited to English-
language publications. In population-based surveys, recent
mendelian randomization studies indicate that changes in hor-
monal status (e.g. with menarche or menopause) might affect
lung function. Another recent study suggested that exogenous
sex steroids may reduce the lung aging in menopausal women.
Low DHEA-S concentrations have been associated with inflam-
matory lung diseases, and greater mortality in COPD patients.
DHEA-S had been associated with improved lung function in
male adolescents with asthma, and nebulized DHEA-S was
reported to improve asthma control. In experimental animal
models, DHEA-S was found to prevent bronchospasm and relax
airway smooth muscles. One cross-sectional study in men,
found significant correlations but no association between
DHEAs and FEV1 and FVC in multivariate analysis. We found no
studies that investigated the associations between DHEA-S lev-
els and lung function decline in women from the general
population.
Added value of this study
We showed that low DHEA-S levels are associated with poor
lung function, reduced FVC and FEV1/FVC ratio in a population-
based sample of about 3000 women from 19 centres and 9
European countries. In longitudinal analyses, low DHEA-S levels
at baseline were associated with 3-fold greater risk of develop-
ing airflow limitation (FEV1/FVC<lower limit of normal) after
an 11-years follow-up.
Implications of all the available evidence
Our findings provide new evidence supporting a beneficial
effect of DHEA-S in women’s respiratory health. Further studies
are needed to assess these relationships in men and to evaluate
if restoring DHEA-S to normal levels might improve respiratory
function and decrease the risk of airflow limitation.1. INTRODUCTION
Sex hormones have biological effects in many non-reproductive
organs. The presence of sex steroid receptors in the lungs and in the
airways suggests that androgens and estrogens might play a role in
the regulation of the respiratory function [1]. However, despite sup-
porting findings from experimental studies, there is little evidence
from clinical or epidemiological studies. In women, hormonal balance
might be especially important, as changes of the hormonal status
such as those occurring with menopause, have been associated with
lung function decline [2,3]. In peripheral tissues, androgens and
estrogens are produced intracellularly from dehydroepiandrosterone
(DHEA) [4]. DHEA is a steroid, which is mainly produced in the zona
reticularis of the adrenal glands in response to adrenocorticotropic
hormone (ACTH). DHEA is mainly secreted as a sulfate ester (DHEA-
S), which is the most abundant sex steroid in human serum. Its con-
centration peaks around the age of 20 and then steadily decreases
with age [4].
There is evidence that DHEA-S can exert immunomodulatory and
anti-inflammatory functions [57]. DHEA-S naturally antagonizes
some of the immunosuppressive and catabolic effects of glucocorti-
coids, and its decline with age is thought to be one of the causes of
immune-senescence [810].
Low DHEA-S levels were associated with all-cause mortality in
several population-based studies [11], and were also observed in
patients with cardiovascular and inflammatory diseases [1219]. No
population-based study has investigated the association of DHEA-S
with lung function decline, which is a significant predictor of mortal-
ity in long term follow-up studies [20]. As low DHEA-S has been asso-
ciated with early death, we hypothesized that DHEA-S concentrations
might be associated with lung function impairment, which may be
mediating this association.
Serum DHEA-S concentrations were measured in women partici-
pating in the European Community Respiratory Health Study (ECRHS)
as part of a program aimed at investigating the associations between
hormonal factors and lung function decline in women [2,21], In this
manuscript, we investigated if DHEA-S levels were associated with
lung function and lung function decline in 10 years in women from
the general population, independently from age, smoking history,
and other potential confounders.
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2.1. Study design and population
The ECRHS (www.ecrhs.org) is an international population-based
cohort study of adults born in 19451970 [22]. Participants under-
went clinical examinations, including spirometry and standardized
interviewer-led questionnaires in 19911993 (ECRHS-1),
19992002 (ECRHS-2) and 20102013 (ECRHS-3). At ECRHS-2 and
ECRHS-3, blood samples were collected in women from centers tak-
ing part in the hormonal measurement protocol. All the women with
spirometry and DHEA-S measurement in at least one of these surveys
were considered for the present analysis. Overall, 2969 women from
19 centers in 9 European countries were included in this study [Table
E1]. Ethical approval was obtained for each center from the appropri-
ate ethics committee, and written consent was obtained from each
participant. This manuscript adheres to the STROBE guidelines.
2.2. Respiratory outcomes
Forced vital capacity (FVC) and forced expiration volume in 1 s
(FEV1) were measured according to the American Thoracic Society
criteria for repeatability. FEV1, FVC, and FEV1/FVC ratio percentage of
predicted and lower limit of normal (LLN) were calculated using the
Global Lung Initiative equations [23]. Airflow limitation was defined
as FEV1/FVC <LLN; restrictive pattern on spirometry was defined as
FVC<LLN in subjects without airflow limitation [23].
2.3. DHEA-S measurements
Blood samples were drawn and stored following standardized
procedures. DHEA-S serum concentrations were determined cen-
trally using an immuno-competitive assay (Elecsys DHEA-S electro-
chemiluminescence immunoassay, Roche Diagnostics, Germany) at
ECHRS-2, while a high-throughput LC-MS/MS system (Aquity UPLC
coupled with a Xevo TQ-S mass spectrometer, Waters Corp., Milford,
MA, USA) was used at ECRHS-3.
To account for the dependency of DHEA-S on age and as the labo-
ratory assessments differed between the two examinations, we
derived age-adjusted DHEA-S z-scores separately for ECRHS-2 and
ECRHS-3, using mixed-effects linear regression models on log-trans-
formed DHEA-S concentrations with age included as independent
variable and study center as a random effect. The resulting z-score
represents how far (in units of the population standard deviation, SD)
a measured concentration is from the mean of a same-age popula-
tion. Participants with a z-score <1 (representing 14.3% of the sam-
ple) were considered as having “low” DHEAs levels.
2.4. Statistical analysis
To investigate the cross-sectional associations of DHEA-S with
subjects’ characteristics and respiratory outcomes, data from ECRHS-
2 and ECRHS-3 were pooled together, and we fitted multilevel mod-
els with subject ID (as a level-2 unit, to account for repeated meas-
ures) nested in the center (level-3). Associations were modeled using
mixed-effects linear or Poisson with robust error variance regres-
sions, with DHEA-S z-score included either as a continuous variable
or as a categorical variable. Body mass index, smoking history, educa-
tion as proxy of socioeconomic status, physical activity, and meno-
pausal status were considered for adjustment. Age was included as
precision variable because of its strong association with spirometry
outcomes. Stratified analyses were performed for median age, to
investigate if a different association was observed in older women
(when DHEA-S is lower), and for menopausal status, as the effects of
DHEA-S might change with the hormonal context.Longitudinal association of DHEA-S z-score at baseline (ECRHS-2)
and lung function decline between ECRHS 2 and 3 was assessed using
linear models. In addition, incidence of new subjects with spirometric
restriction pattern and airflow limitation was evaluated at follow-up,
and mixed-effects Poisson regression models were used to derive
incident rate ratios (IRR) in function of baseline DHEA-S z-score.
Sensitivity analyses for the associations of DHEA-S with spiromet-
ric outcomes were performed after exclusion from the models of: 1)
corticosteroids users, as corticosteroids are known to affect the adre-
nal function and DHEA-S secretion; 2) women with asthma, as
DHEA-S has been associated in literature with asthma occurrence; 3)
current smokers, to avoid potential residual confounding by smoking
which can significantly alter both lung function and DHEA-S secre-
tion; 4) women sampled in the ECHRS symptomatic sample, to ascer-
tain that the results were not driven by unspecified respiratory
conditions.
In all models, women with missing data on a covariate were
removed from the models. The statistical analyses were performed
using STATA v14.2 (StataCorp, College Station, TX, USA).
Additional details are provided in the online data supplement.
[Text E1]
3. RESULTS
3.1. Sample characteristics and associations with DHEA-S
A total of 3770 observations with valid lung function and DHEA-S
measurements (n = 2045 at ECRHS-2 and n = 1725 at ECRHS-3) were
considered for the cross-sectional analyses; 801 women had DHEA-S
measured at both ECRHS-2 and ECRHS-3 (repeated measures).
Among the 2045 women with DHEA-S and lung function at ECRHS-2,
1216 were followed-up with spirometry and clinical interviews at
ECRHS-3 (average follow-up time: 11.0§ 1.1 years) and were
included in the longitudinal analyses.[Table E1]
The distribution of the covariates by survey and their associations
with DHEA-S levels are shown in Table 1. Compared to lifetime non-
smokers, current smokers had significantly higher DHEA-S concen-
trations, while ex-heavy smokers had lower DHEA-S concentrations.
DHEA-S concentrations were also higher in overweight women
(Table 2). We observed no association of age-adjusted DHEA-S z-
score with menopausal status, as well as with passive smoke, school
education, and physical activity. Both inhaled and oral corticosteroid
use in the past year were significantly associated with lower DHEA-S
levels (p<0.001).
3.2. Cross-sectional associations of DHEA-S levels with lung function
indices
The cross-sectional associations of DHEA-S with pre-bronchodila-
tor FEV1, FVC and FEV1/FVC ratio suggest that the association with
FEV1 and FVC might not be linear [Fig. 1]. In particular, women with
low DHEA-S (z-score<1) had significantly lower FEV1 and FVC com-
pared to women with normal levels of DHEA-S for their age (z-score
between 0.5 and +0.5), while women with DHEA-S z-score above 1
did not have significantly different FEV1 or FVC. Accordingly, it was
found that the proportion of women with low DHEA-S was signifi-
cantly higher among women with a restrictive pattern (21.8%) than
among women with normal lung function (13.5%). This difference
was found also among never-smokers or ex-smokers with a cumula-
tive history of less than 15 pack-years tobacco smoke, in whom the
percentage of women with low DHEA-S reached 24.5% in women
with a restrictive spirometric pattern (vs. 13.8% in women with nor-
mal lung function).
For modeling both linear and non-linear associations, the associa-
tions of lung function outcomes with DHEA-S were estimated with z-
scores included either as a continuous or dichotomous variable
Table 1
Participants’ characteristics by survey. Distributions are expressed as number (per-
centage), median [range] or mean § standard deviation.
ECRHS-2 n = 2045 ECRHS-3 n = 1725
Age, years 43.4 [28.0,56.8] 53.7 [39.7,66.9]
Smoking habits
Non smokers 928 (45.4%) 774 (44.9%)
Past smokers with <15py 387 (18.9%) 472 (27.4%)
Past smokers with 15py 119 (5.8%) 155 (9.0%)
Current smokers with<15py 249 (12.2%) 102 (5.9%)
Current smokers with 15py 272 (13.3%) 132 (7.7%)
Smokers with unknown py 86 (4.2%) 89 (5.2%)
missing 4 (0.2%) 1 (0.1%)
Exposure to passive smoke in the
last 12 months
No 1275 (62.4%) 1376 (79.8%)
Yes 759 (37.1%) 337 (19.5%)
missing 11 (0.5%) 12 (0.7%)
Body mass index,
<25 kg/m2 1194 (58.4%) 736 42.7%)
[2530) kg/m2 591 (28.9%) 578 (33.5%)
30 kg/m2 258 (12.6%) 400 (23.2%)
missing 2 (0.1%) 11 (0.6%)
Age completed full time education
16years or younger 357 (17.5%) 252 (14.6%)
1720 years 653 (31.9%) 614 (35.6%)
21years or older 1030 (50.4%) 818 (47.4%)
missing 5 (0.2%) 41 (2.4%)
Vigorous physical activity
No 1207 (59.0%) 979 (56.8%)
Yes 808 (39.5%) 742 (43.0%)
missing 30 (1.5%) 4 (0.2%)
Menstrual Periods
Regular 1199 (58.6%) 464 (26.9%)
Never been regular 120 (5.9%) 72 (4.2%)
Recently irregular 220 (10.8%) 139 (8.1%)
Have stopped (>6 months) 464 (22.7%) 840 (48.7%)
missing 42 (2.0%) 210 (12.2%)
Use of corticosteroids in the last 12
months
No 1824 (89.2%) 1538 (89.2%)
Inhaled corticosteroids only 150 (7.3%) 68 (3.9%)
Oral corticosteroids 38 (1.6%) 20 (1.2%)
missing 33 (1.6%) 99 (5.7%)
FEV1, (mL) 2959§ 505 2574§ 500
FEV1,% of predicted 98.7§ 13.5 94.4§ 14.9
FVC, (mL) 3675§ 588 3392§ 593
FVC,% of predicted 99.8§ 12.6 99.0§ 13.5
FEV1/FVC ratio (%) 80.6§ 6.6 75.9§ 6.5
FEV1/FVC ratio,% of predicted 98.5§ 7.8 94.7§ 7.9
Airflow limitation (FEV1/FVC<LLN) 129 (6.3%) 174 (10.1%)
Restrictive pattern on spirometry
(FVC<LLN and FEV1/FVCLLN)
81 (4.2%) 62 (4.0%)
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DHEA-S had significantly lower FEV1 and FVC (2.0 and 1.7% of
predicted, respectively) than women with higher DHEA-S. For FEV1/
FVC ratio, a linear increase of one unit in DHEA-S z-score was associ-
ated with an increase of +0.3 in FEV1/FVC% of predicted.
Although different methods were used at ECRHS 2 and ECRHS 3 to
measure DHEA-S, the associations of z-score DHEA-S with FEV1 and
FVC were similar at the two surveys (Table E3). No significant interac-
tion was found between DHEA-S and age or between DHEA-S and
menopausal status (Table E4).
When analyzing spirometric outcomes as binary variables, we
found that women with low DHEA-S had a 62% greater risk of having
restrictive pattern (RR: 1.62, 95%CI: 1.112.38; p = 0.013) and 35%
greater risk of having pre-bronchodilator airflow limitation (RR: 1.35,
95%CI: 1.081.69; p = 0.008) than women with higher DHEA-S
[Fig. 2]. When we repeated the cross-sectional analysis using only
data at ECRHS-3, where post-bronchodilator measures were avail-
able, we found that low DHEA-S was also associated with a 66%significantly greater risk of post-bronchodilator airflow limitation
(Table E3).
3.3. Longitudinal associations of DHEA-S levels with lung function
decline and incidence of spirometric restriction and airflow limitation
The characteristics of women who did and did not participate in
both surveys and were included in the longitudinal analyses are
shown in the online supplement.[Table E5] A faster decline in pre-
bronchodilator FEV1/FVC ratio (0.13% of predicted/year, p = 0.003)
was observed in women with low DHEA-S compared to those who
had higher DHEA-S levels at baseline.[Table E6] DHEA-S at baseline
was not associated with FVC decline.
After excluding women with prevalent airflow limitation at
ECRHS-2, women with low DHEA-S at baseline had a 3-fold greater
risk to develop pre-bronchodilator airflow limitation at ECRHS-3
(IRR =3.43, p<0.001) (Table 4). This association showed a significant
interaction with age (p for interaction=0.013), and low DHEA-S was
prospectively associated with a greater risk of developing airflow
limitation in women older than the median age (i.e.age43 years at
baseline, IRR=9.59; 95%CI:4.0322.8), but not in younger women
(IRR=1.32;95%CI:0.483.68). Low DHEA-S at baseline was also associ-
ated with a higher risk of post-bronchodilator airflow limitation at
ECRHS-3 (IRR =2.81, p = 0.040) (Table 4). No association between
DHEA-S at baseline and having restrictive pattern at follow-up was
observed, but the number of incident cases was very low.
3.4. Sensitivity analyses
We found similar results when data from ECRHS 2 and ECRHS 3
were analyzed separately for cross-sectional associations (Table E4).
The cross-sectional associations of DHEA-S with lung function out-
comes were less strong, but still generally statistically significant,
when women who used corticosteroids or had asthma were excluded
from the analyses (Table 3, Fig. 2, Table E7). The sensitivity analyses
performed considering only women sampled in the ECRHS “random
sample” to exclude potential bias related to other respiratory condi-
tions, as well as in “non-smokers only” to avoid potential residual
confounding by smoking, confirmed the main results (Table 3, Fig. 2,
Table E7). The longitudinal association between low DHEA-S and
higher risk of developing airflow limitation remained significant in
the sensitivity analyses (Table E8).
4. DISCUSSION
To the best of our knowledge, this is the first epidemiological
study investigating the association between DHEA-S levels and lung
function in adult women from the general population, and the first
longitudinal study investigating the associations of DHEA-S with lung
function decline. We found that women with low DHEA-S levels
were significantly more likely to have airflow limitation and restric-
tive pattern on spirometry than women with higher DHEA-S levels.
Moreover, in longitudinal analyses, having low DHEA-S was associ-
ated with a greater risk of developing airflow limitation after 11-
years of follow-up.
These associations were independent from potential confounders,
such as smoking habits and use of corticosteroids, which were found
to affect the concentration of DHEA-S. In fact, DHEA-S levels were
severely reduced in women treated with oral corticosteroids, but also
in women who used only inhaled corticosteroids, reflecting that even
inhaled corticosteroids may have systemic effects and cause adrenal
suppression. Nicotine has also been reported to affect the HPA axis
[24]. In our study, current smokers had higher DHEA-S concentra-
tions than non-smokers, confirming previous reports [25].
Women who had DHEA-S concentrations lower than one standard
deviation from the average for their age had significantly lower FEV1
Table 2
Associations of women’s characteristics with DHEA-S z-score. *adjusted for age plus all the other covariates included in the table.
Unadjusted Beta (95%CI) p-value Adjusted* beta (95%CI) p-value
Smoking habits
Non smokers reference  reference 
Past smokers with <15py 0.00 (0.08,0.08) .921 0.00 (0.08,0.09) .942
Past smokers with 15py 0.04 (0.16,0.09) .575 0.13 (0.26,0.00) .052
Current smokers with<15py 0.18 (0.07,0.29) .001 0.18 (0.06,0.29) .003
Current smokers with 15py 0.23 (0.13,0.33) <0.001 0.21 (0.10,0.33) <0.001
Smokers with unknown py 0.00 (0.14,0.15) .958 0.02 (0.18,0.14) .810
Exposure to passive smoke in the last 12 months
No Reference  Reference 
Yes 0.09 (0.02,0.16) .008 0.04 (0.06,0.12) .355
Body mass index,
<25 kg/m2 Reference  Reference 
[2530) kg/m2 0.09 (0.02,0.16) .014 0.08 (0.01,0.16) .023
30 kg/m2 0.03 (0.06,0.12) .488 0.05 (0.04,0.14) .282
Age completed full time education
16years or younger 0.03 (0.13,0.07) .554 0.07 (0.17,0.04) .213
1720 years Reference  Reference 
21years or older 0.01 (0.08,0.06) .705 0.02 (0.09,0.05) .569
Vigorous physical activity
No Reference  Reference 
Yes 0.05 (0.11,0.02) .160 0.05 (0.11,0.02) .173
Menstrual Periods
Regular reference  reference 
Never been regular 0.05 (0.19,0.09) .447 0.06 (0.20,0.08) .386
Recently irregular 0.11 (0.01,0.09) .038 0.07 (0.04,0.18) .204
Have stopped (>6 months) 0.02 (0.09,0.05) .523 0.06 (0.14,0.03) .192
Use of corticosteroids in the last 12 months
No reference  reference 
Inhaled corticosteroids only 0.41 (0.54,0.28) <0.001 0.41 (0.54,0.27) <0.001
Oral corticosteroids 0.82 (1.05,0.59) <0.001 0.77 (1.01,0.52) <0.001
G. Pesce et al. / EClinicalMedicine 23 (2020) 100389 5and FVC than women with higher DHEA-S, resulting in a greater risk
of both airflow limitation and restrictive pattern on spirometry. There
are no other studies in women to be compared to ours. We only
found similar investigation in two cohorts of community-dwelling
men: the Tromsø and the Busselton studies [26,27]. In these cross-
sectional studies, including respectively 2197 Norwegian and 1768
Australian adult men, high serum levels of testosterone and dehydro-
testosterone, but not estrogens, were significantly associated with
better lung function [26,27]. In the Tromsø study, DHEA-S concentra-
tions were also measured, but no significant linear association was
found between FEV1 and FVC and DHEA-S after adjustments [26].Fig. 1. Women’s spirometric measures by DHEAS z-score group. FEV1 (a), FVC (b), and FEV1
parisons between different DHEA-S levels are shown in Table E2 in the Online Supplement.However, our findings suggest that the associations between DHEA-S
and these lung function outcomes might not be linear. Moreover, as
the Tromsø cohort was composed exclusively of men, the difference
with our findings might be due to the lower concentrations of DHEA-
S in women as compared to men, to different distribution of unmea-
sured confounders, or indicate that DHEA-S has a different impact on
respiratory function in men and women.
Considering that DHEA-S is almost the exclusive source of andro-
gens in peripheral tissues in women [4], these data together suggests
that DHEA-S, directly or indirectly through its androgenic metabo-
lites, might contribute in sustaining the respiratory function. Since/FVC ratio (c) are expressed as percentage of predicted. P-values for the pairwise com-
Table 3
Association of DHEA-S z-scores with FEV1, FVC, and FEV1/FVC. Results frommain model and sensitivity analyses.
DHEA-S z-score (continuous) Low* DHEA-S vs.higher
Obs. Beta (95% CI) p-value Beta (95% CI) p-value
FEV1 (% of predicted)
Unadjusted 3516 0.52 (0.35,1.00) .036 2.18 (3.52,0.85) .001
Main modely 3516 0.65 (0.18,1.12) .007 2.02 (3.33,0.71) .002
w/o CS usersy1 3245 0.49 (0.00,0.97) .049 1.65 (3.01,0.28) .018
w/o asthmay2 3089 0.33 (0.15,0.82) .180 1.52 (2.90,0.15) .030
w/o current smokersy3 2633 0.92 (0.38,1.46) .001 2.35 (3.82,0.87) .002
w/o symptomatic sampley4 2895 0.59 (0.06,1.12) .029 1.99 (3.44,0.54) .007
FVC (% of predicted)
Unadjusted 3460 0.27 (0.16,0.70) .219 1.70 (2.90,0.49) .006
Main modely 3460 0.34 (0.08,0.77) .114 1.64 (2.83,0.46) .006
w/o CS usersy1 3193 0.20 (0.25,0.64) .386 1.40 (2.65,0.15) .028
w/o asthmay2 3037 0.06 (0.40,0.52) .800 1.33 (2.62,0.04) .043
w/o current smokersy3 2586 0.72 (0.23,1.21) .004 2.15 (3.49,0.80) .002
w/o symptomatic sampley4 2848 0.29 (0.20,0.78) .241 1.77 (3.11,0.43) .010
FEV1/FVC ratio (% of predicted)
Unadjusted 3412 0.35 (0.08,0.62) .010 0.60 (1.36,0.15) .118
Main modely 3412 0.31 (0.04,0.58) .024 0.55 (1.28,0.19) .147
w/o CS usersy1 3151 0.29 (0.02,0.56) .033 0.28 (1.03,0.48) .469
w/o asthmay2 2995 0.28 (0.02,0.55) .038 0.26 (1.01,0.50) .505
w/o current smokersy3 2552 0.27 (0.04,0.57) .086 0.35 (1.18,0.48) .409
w/o symptomatic sampley4 2812 0.33 (0.04,0.62) .061 0.30 (1.09,0.49) .456
FEV1: Forced expiratory volume in the 1st second, FVC: Forced vital capacity, CS: corticosteroids.
*low DHEAS is defined as having Z-score < 1.
y adjusted for age, BMI, smoking history, passive smoke exposure, physical activity, schooling and periods.
Sensitivity analyses were performed in (1) women who were not using corticosteroids; (2) women who did not report asthma; (3)
after excluding women recruited as part of the symptomatic sample; (4) non-smokers only.
Statistically significant associations (p<0.05) are shown in bold; borderline associations (0.05p<0.10) are in italics.
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DHEA-S deficiency contributes to respiratory muscle weakness [9],
with a simultaneous restrictive lung function impairment. In our
study, low DHEA-S was associated with restrictive pattern on spirom-
etry only in the cross-sectional analysis, while it was not associated
with FVC decline in the longitudinal analysis. If the association was
causal, this might point toward a short-term, maybe reversible, effectFig. 2. Cross sectional associations of DHEA-S z-scores (low DHEA-S vs. higher) with the
(FVC<LLN and FEV1/FVCLLN). Results from main model (MM) and sensitivity analyses. Mo
sure, physical activity, schooling and periods (main model); I: MM with exclusion of cortico
current smokers, IV: MMwith exclusion of women recruited in the ECRHS symptomatic samof DHEA-S deficiency on pulmonary vital capacity. Noteworthy,
among never-smokers or light smokers, one out of four women with
a restrictive pattern was found to have low DHEA-S levels.
As regards airflow limitation, we found significant relationships in
the cross-sectional analyses and in the longitudinal analysis. Low
DHEA-S at baseline was prospectively associated with faster FEV1/
FVC ratio decline and with about 3-fold greater risk of developingrisk of airflow limitation (FEV1/FVC<LLN) and of restrictive pattern on spirometry
dels: U: unadjusted; MM: adjusted for age, BMI, smoking history, passive smoke expo-
steroids users, II: MM with exclusion of women with asthma, III: MM with exclusion of
ple.
Table 4
Longitudinal associations of DHEAS z-scores with incidence of spirometric restrictive pattern (FVC < LLN and FEV1/FVC  LLN) and pre- and post-bronchodilator airway limita-
tion (FEV1/FVC < LLN).
Person-years Incident cases Rates x1000/year Unadjusted IRR (95% CI) p Adjusted^ IRR (95% CI) p
Spirometric restritive pattern
Low DHEA-S* 1559 3 1.9 1.07 (0.31,3.71) .916 1.40 (0.39,5.04) .611
Higher DHEA-S 10,129 17 1.7 reference reference
Air flow limitation (pre-bronchodilator)
Low DHEA-S* 1699 18 10.6 3.38 (1.92,5.93) <0.001 3.43 (1.91,6.14) <0.001
Higher DHEA-S 11,792 42 4.0 reference reference
Air flow limitation (post-bronchodilator)
Low DHEA-S* 1665 6 3.6 3.15 (1.21,8.21) .019 2.81 (1.05,7.53) .040
Higher DHEA-S 10,277 16 1.6 reference reference
IRR: incidence rate ratio. ^IRR are adjusted for age and BMI at baseline, change in BMI, history of smoking between the two examinations. *z-score <1.
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bronchodilator.
Our findings on airflow limitation are consistent with previous
studies that reported an association between low DHEA-S and
asthma, of which airway obstruction is one of the principal features
[1619]. Although the cross-sectional association of DHEA-S with
airflow limitation was not significant after excluding women with
asthma, the magnitude of the association in women without asthma
was similar as in the total sample. Furthermore, the longitudinal
association of baseline DHEA-S with airflow limitation incidence
remained significant in women without asthma. DHEA-S might
impact on airflow limitation through its immunomodulatory and
anti-inflammatory properties. In vitro studies have shown that
DHEA-S has direct effects on immune cells migration and inhibits the
secretion of pro-inflammatory cytokines (namely IL-6, IL-2, IL-10,
and TNF) from several cell types in humans [58]. The hypothetic
mechanisms of action might be both via direct inhibition of NF-kB
and indirectly via downstream testosterone and estrogens [58]. In
addition, in vivo studies have shown that DHEA-S and testosterone
can act as bronchoactive steroids, regulating airway contractility by
relaxing the airway smooth muscles and preventing bronchospasm
[28]. Together, these data suggest that DHEA-S may attenuate airway
inflammation and bronchospasm and, vice-versa, low DHEA-S may
increase the hyper-responsiveness of smooth muscle surrounding
the airways and inflammation-driven loss of elastic recoil of lungs
and large airways [29], contributing to the development of airflow
limitation.
As low DHEA-S was prospectively associated also with incident
fixed airflow limitation at follow-up, we hypothesize that low DHEA-
S might be a risk factor for the development of COPD. Of note, a
recent 6-year follow-up study reported that low DHEA-S levels were
associated with greater mortality in COPD patients with acute exacer-
bation [30], suggesting that DHEA-S might be linked to both disease
development and progression.
Previous reports showed that patients with asthma or using corti-
costeroids have low DHEA-S [1619,31]. In our study, however, we
found that the associations of DHEA-S with airflow limitation at fol-
low-up were not limited to women having a respiratory disease or
taking corticosteroids at baseline.
The strengths of our study include the large sample size, longitu-
dinal design, and the use of a standardized protocol across centers,
with spirometry and serum biomarkers collected in women from the
general population.
We recognize that measurements of DHEA-S using two different
methods is a potential limitation of our study. However through
transformation of DHEA-S concentrations in z-scores we were able to
harmonize and combine the measurements obtained by immunoas-
say and by mass spectrometry. Although the two methods have dif-
ferent sensitivity and specificity (with LC-MS/MS considered the gold
standard for DHEA-S measurement), the associations found in the
main analyses were overall confirmed when performing separateanalyses for the measurements obtained by immunoassay and mass-
spectrometry, supporting the validity of our findings.[Table E3] Our
observation that DHEA-S seemed associated with incident airflow
limitation especially at older ages suggests that there might be a
threshold effect, which needs further investigation.
As only women were sampled, the results of this study may not be
generalized to men. Furthermore, as our sample was selected from
the general population and relatively young at baseline, the number
of incident cases of airflow limitation and restrictive pattern on spi-
rometry was limited. Although we do acknowledge these limits, this
is the first study with lung function in women and the only study
with longitudinal data on lung function decline. Furthermore, we
found significant associations with the incidence of airflow limitation.
Our study - with repeated measures of DHEA-S and spirometry data
on such a large sample  provides valuable evidence on the associa-
tion between DHEA-S and lung function decline.
Independently from smoking habits and use of corticosteroids,
low DHEA-S was associated with impaired lung function in women
and predicted airflow limitation. Our findings provide new evidence
supporting a protective role of DHEA-S in respiratory health. It might
be particularly relevant to investigate DHEA-S deficiency in non-
smoking women with unexplained airflow restriction. Further stud-
ies are needed to assess these relationships in men and to evaluate if
restoring DHEA-S to normal levels might improve respiratory func-
tion and decrease the risk of developing airflow limitation.
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